TR201900778T4 - İmmünojenik bileşim. - Google Patents

İmmünojenik bileşim. Download PDF

Info

Publication number
TR201900778T4
TR201900778T4 TR2019/00778T TR201900778T TR201900778T4 TR 201900778 T4 TR201900778 T4 TR 201900778T4 TR 2019/00778 T TR2019/00778 T TR 2019/00778T TR 201900778 T TR201900778 T TR 201900778T TR 201900778 T4 TR201900778 T4 TR 201900778T4
Authority
TR
Turkey
Prior art keywords
protein
saccharide
saccharides
meningitidis
polysaccharides
Prior art date
Application number
TR2019/00778T
Other languages
English (en)
Turkish (tr)
Inventor
Vinayak Kapre Subhash
Shankar Pisal Sambhaji
Original Assignee
Serum Institute Of India Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute Of India Private Ltd filed Critical Serum Institute Of India Private Ltd
Publication of TR201900778T4 publication Critical patent/TR201900778T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
TR2019/00778T 2012-01-30 2013-01-29 İmmünojenik bileşim. TR201900778T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN281MU2012 2012-01-30

Publications (1)

Publication Number Publication Date
TR201900778T4 true TR201900778T4 (tr) 2019-02-21

Family

ID=54259032

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/00778T TR201900778T4 (tr) 2012-01-30 2013-01-29 İmmünojenik bileşim.

Country Status (17)

Country Link
US (1) US9198977B2 (enExample)
EP (1) EP2809349B1 (enExample)
JP (1) JP6042455B2 (enExample)
KR (1) KR101897317B1 (enExample)
CN (1) CN104302315B (enExample)
BR (1) BR112014018815B1 (enExample)
CA (1) CA2863178C (enExample)
DK (1) DK2809349T3 (enExample)
ES (1) ES2707294T3 (enExample)
HU (1) HUE040914T4 (enExample)
MX (1) MX354103B (enExample)
PT (1) PT2809349T (enExample)
RU (1) RU2634405C2 (enExample)
SG (1) SG11201404447WA (enExample)
SI (1) SI2809349T1 (enExample)
TR (1) TR201900778T4 (enExample)
WO (1) WO2013114268A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE045482T2 (hu) 2005-06-27 2019-12-30 Glaxosmithkline Biologicals Sa Immunogén készítmény
NZ708523A (en) * 2012-11-21 2018-09-28 Serum Institute Of India Pvt Ltd Production of high yields of bacterial polysaccharides
MX365726B (es) 2013-08-24 2019-06-11 Bharat Biotech Int Ltd Vacuna bacteriana y metodos para la fabricacion de la misma.
EP2921856B1 (en) 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
US10729780B2 (en) 2015-06-08 2020-08-04 Serum Institute Of India Private Ltd. Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof
EP3316903A4 (en) * 2015-07-04 2019-01-09 Bharat Biotech International Limited POLYSACCHARIDE VACCINE FORMULATIONS AND METHOD FOR THE INDUSTRIAL MANUFACTURE OF BACTERIAL POLYSACCHARIDES
MX2018010920A (es) * 2016-03-15 2019-03-06 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd Nuevos conjugados de polisacarido-proteina, y procedimiento para obtener los mismos.
CN106110316A (zh) * 2016-06-27 2016-11-16 北京智飞绿竹生物制药有限公司 一种肺炎球菌结合物组合疫苗的制备方法
CN109890413B (zh) * 2016-09-02 2024-04-16 赛诺菲巴斯德股份有限公司 脑膜炎奈瑟氏菌疫苗
CN106397537B (zh) * 2016-10-13 2020-01-07 李红臣 一种高效快速的多糖蛋白结合疫苗纯化分析方法
US11739356B2 (en) * 2017-05-05 2023-08-29 Serum Institute Of India Private Limited Method for removal of impurities from bacterial capsular polysaccharide based preparations
JP2020525495A (ja) * 2017-06-27 2020-08-27 エムエスディー ウェルカム トラスト ヒルマン ラボラトリーズ プライベート リミテッドMsd Wellcome Trust Hilleman Laboratories Pvt.Ltd. 新規の多価多糖類・タンパク質のコンジュゲートワクチン組成物及びその製剤
US20200353064A1 (en) * 2018-01-29 2020-11-12 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Novel meningococcal vaccine composition and process thereof
WO2019198096A1 (en) * 2018-04-11 2019-10-17 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Tetravalent meningococcal vaccine composition and process to prepare thereof
JOP20200214A1 (ar) 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US12053515B2 (en) 2020-08-10 2024-08-06 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F
CN118078981A (zh) * 2024-04-26 2024-05-28 成都康华生物制品股份有限公司 一种基于双蛋白载体的五价脑膜炎球菌多糖结合疫苗的制备方法及其产品

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
EP1946769B1 (en) * 2000-06-29 2012-05-30 SmithKline Beecham Biologicals S.A. Multivalent vaccine composition with reduced dose of Haemophilus influenzae type B
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
ES2397923T3 (es) * 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos
GB0513069D0 (en) * 2005-06-27 2005-08-03 Glaxosmithkline Biolog Sa Immunogenic composition
HUE045482T2 (hu) * 2005-06-27 2019-12-30 Glaxosmithkline Biologicals Sa Immunogén készítmény
CN102973929B (zh) * 2005-09-01 2017-04-26 诺华疫苗和诊断有限两合公司 含血清群c脑膜炎球菌的多价疫苗
JP5792920B2 (ja) * 2005-12-22 2015-10-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB0703369D0 (en) * 2007-02-21 2007-03-28 Health Prot Agency Compositions Comprising Capsular Polysaccharides and Their Use as Vaccines
BR122022002139B1 (pt) * 2009-12-17 2022-08-23 Fina Biosolutions, Llc Processo de conjugação de carboidratos na preparação de vacinas conjugadas e suas respectivas vacinas
EP2852414B9 (en) * 2012-05-22 2020-12-09 GlaxoSmithKline Biologicals SA Meningococcus serogroup x conjugate

Also Published As

Publication number Publication date
BR112014018815A2 (enExample) 2017-06-20
RU2634405C2 (ru) 2017-10-26
SG11201404447WA (en) 2014-08-28
CA2863178C (en) 2021-04-06
US20140377302A1 (en) 2014-12-25
WO2013114268A1 (en) 2013-08-08
EP2809349A1 (en) 2014-12-10
CN104302315A (zh) 2015-01-21
RU2014134288A (ru) 2016-03-20
CA2863178A1 (en) 2013-08-08
JP6042455B2 (ja) 2016-12-14
SI2809349T1 (sl) 2019-03-29
KR20140123553A (ko) 2014-10-22
ES2707294T3 (es) 2019-04-03
HUE040914T4 (hu) 2019-05-28
MX354103B (es) 2018-02-13
KR101897317B1 (ko) 2018-09-11
BR112014018815A8 (pt) 2017-07-11
US9198977B2 (en) 2015-12-01
EP2809349A4 (en) 2015-08-26
EP2809349B1 (en) 2018-12-19
DK2809349T3 (da) 2019-02-18
PT2809349T (pt) 2019-02-01
MX2014009250A (es) 2015-03-19
BR112014018815B1 (pt) 2022-07-12
CN104302315B (zh) 2018-02-06
JP2015509111A (ja) 2015-03-26

Similar Documents

Publication Publication Date Title
MX354103B (es) Composicion inmunogenica.
PH12021551159A1 (en) Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
MX2025002072A (es) Un conjugado de un agente citotoxico y una molecula de union a celulas con enlazadores ramificados
MY148110A (en) Immunogenic composition
BR112012019757B8 (pt) Composição imunogênica, e, uso de uma mistura de conjugado de polissacarídeo-proteína multivalente
EP2408470A4 (en) SOLUBLE NONDEPOT INSULIN CONJUGATE AND ITS USE
PH12014501887A1 (en) Neisseria meningitidis compositions and methods thereof
JP2014218516A5 (enExample)
Danieli et al. Synthesis of Staphylococcus aureus type 5 capsular polysaccharide repeating unit using novel L-FucNAc and D-FucNAc synthons and immunochemical evaluation
BR112020004509A8 (pt) Conjugado polissacarídeo-proteína carreadora, composição imunogênica compreendendo o mesmo e uso do referido conjugado
NZ595291A (en) Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
AR060187A1 (es) Composicion inmunogenica
JP2013079285A5 (enExample)
RU2009130447A (ru) Модифицированные сахариды
RU2014151567A (ru) Конъюгат менингококка серогруппы х
BRPI0206672B8 (pt) composição imunológica, vacina conjugada tetravalente e vacina meningocócica multivalente
IN2012MN02262A (enExample)
HRP20240433T1 (hr) Cjepivo protiv neisseria meningitidis
IN2014DN09791A (enExample)
HRP20090607T8 (en) Combined meningococcal conjugates with common carrier protein
RU2007102016A (ru) Пространственный анализ конъюгатов сахаридов с помощью gpc и sec-mals
JP2015509111A5 (enExample)
BRPI0411875A (pt) método de imunização contra os sorogrupos a e c de neisseria meningitidis
WO2015052684A3 (en) Polysaccharide-protein conjugates with enhanced immunogenicity and rapid high yielding process of preparation thereof
FI2968427T3 (fi) Konjugaatti sienisoluseinämän polysakkarideihin kohdentuvien vasta-aineiden indusoimiseksi